This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Abiomed Hits New 52-Week High: 3 Factors Driving the Stock
by Zacks Equity Research
Abiomed (ABMD) recently reported strong preliminary third-quarter fiscal 2018 results.
Becton, Dickinson Completes Enrollment in Lutonix DCB Trial
by Zacks Equity Research
Becton, Dickinson's (BDX) focus in the Balloon-Angioplasty space is expected to lend the company a competitive edge in the niche MedTech markets.
Becton, Dickinson Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Becton, Dickinson (BDX) rides on favorable regulatory developments and strategic acquisitions.
5 Reasons Why McKesson Deserves a Place in Your Portfolio
by Zacks Equity Research
McKesson (MCK) continues to pursue deals, divestitures and acquisitions to drive growth. The company's impressive performance in 2017 accounts for its potential to sustain the momentum.
Baxter (BAX) Launches Arisure Closed System Transfer Device
by Zacks Equity Research
Baxter's (BAX) Arisure Closed System reduces exposure risk of healthcare professionals to needles. Also, the latest development promotes safe handling of hazardous drugs.
Integra LifeSciences Estimates Strong Revenue Figures for Q4
by Zacks Equity Research
Integra LifeSciences (IART) sees strong organic growth in the company's Specialty Surgical Solutions as well as Orthopedics and Tissue Technologies businesses.
Surmodics (SRDX) Poised on Core Business Amid Forex Woes
by Zacks Equity Research
Surmodics' (SRDX) top line benefits from strong sales in Medical Device and IVD businesses. However, foreign currency is a headwind.
Abaxis' (ABAX) Preliminary Results for Q3 Cheer Investors
by Zacks Equity Research
Abaxis (ABAX) expects substantial tax savings from the recent U.S. tax reform.
Hill-Rom (HRC) Estimates Strong Revenue Figures for Q1
by Zacks Equity Research
Hill-Rom (HRC) expects substantial tax savings from the recent U.S. tax reform.
NuVasive Q4 Preliminary Results Fail to Cheer Investors
by Zacks Equity Research
NuVasive (NUVA) continues to witness sequential growth in international revenues and expects substantial tax savings from the recent U.S. tax reform.
DexCom Estimates Strong Revenue Figures for Q4 and 2017
by Zacks Equity Research
Dexcom (DXCM) to gain from strong sensor volumes, international revenues and expanding worldwide patient base in 2018.
AngioDynamics (ANGO) Misses on Earnings, Revenues in Q2
by Zacks Equity Research
Dwindling revenues in two major segments hurt AngioDynamics' (ANGO) second-quarter results.
McKesson Buys RxCrossroads from CVS Health for $735 Million
by Zacks Equity Research
McKesson (MCK) has been actively pursuing deals, divestitures and acquisitions to drive growth. The latest buyout will boost Specialty Health business.
Walgreens Boots (WBA) Tops Q1 Earnings, Margins Decline
by Zacks Equity Research
Walgreens Boots (WBA) surpasses the Zacks Consensus Estimate for both the counts in Q1 on continued prescription growth and strength in the Retail Pharmacy USA division.
Neogen (NEOG) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Neogen (NEOG) rides high on balanced growth across all business segments in Q2.
Entellus (ENTL) Nears 52-Week High: What's Driving It?
by Zacks Equity Research
Entellus Medical Inc. (ENTL) gains from latest technology and promising revenue trends.
LabCorp Grapples With Reimbursement Cuts, Stiff Competition
by Zacks Equity Research
LabCorp (LH) faces intense competition from hospital-affiliated labs, primarily on the basis of quality of service.
Stryker's Global Foothold Strong Amid Product Recall Issue
by Zacks Equity Research
Stryker (SYK) enjoys strong foothold in the European and Australian markets. On the flip side, the company witnesses lower demand for health care products.
Anika Therapeutics Receives FDA Nod for Bone Repair Therapy
by Zacks Equity Research
Anika Therapeutics' (ANIK) FDA approved HA-based injectable bone repair therapy provides a commercial edge to regenerative portfolio.
5 Reasons Why You Should Buy Abiomed (ABMD) Stock Right Now
by Zacks Equity Research
Abiomed (ABMD) gains from solid product portfolio. Also, impressive performance on the bourses instills investor's optimism on the stock.
Cogentix (CGNT) Stock Near 52-Week High: More Room to Run?
by Zacks Equity Research
Cogentix Medical (CGNT) stock continues to hover around the 52-week high mark reached on Dec 27, courtesy of its new strategies.
Robust Pipeline Aids Edwards Lifesciences, Rising Costs Ail
by Zacks Equity Research
Edwards Lifesciences' (EW) pipeline building to fortify foothold across all operating businesses bodes well. Also, the TAVR adoption rate across Japan and the European countries is impressive.
Align Rides on Balanced Segmental Growth Amid Stiff Contest
by Zacks Equity Research
Align (ALGN) gains from balanced sales growth across all its channels of late, primarily on high InvisAlign Technology case volumes.
New Strong Sell Stocks for November 1st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Integer (ITGR) Q2 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Integer's (ITGR) strong performance in the Cardio and Vascular business was a key highlight in second quarter 2017.